JP2020518571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518571A5 JP2020518571A5 JP2019558778A JP2019558778A JP2020518571A5 JP 2020518571 A5 JP2020518571 A5 JP 2020518571A5 JP 2019558778 A JP2019558778 A JP 2019558778A JP 2019558778 A JP2019558778 A JP 2019558778A JP 2020518571 A5 JP2020518571 A5 JP 2020518571A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- ring
- independently
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- -1 -NR 41 R 42 Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000006413 ring segment Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- NJCUGSHOGLOYFF-UHFFFAOYSA-N CC(C)Cc1ccc(C(CC2)CC=C2c2cnc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)nc2)cc1 Chemical compound CC(C)Cc1ccc(C(CC2)CC=C2c2cnc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)nc2)cc1 NJCUGSHOGLOYFF-UHFFFAOYSA-N 0.000 description 2
- XBZOBROMNOVPDV-UHFFFAOYSA-N CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CCCCCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 XBZOBROMNOVPDV-UHFFFAOYSA-N 0.000 description 2
- NZLZPEXQNSVHJE-UHFFFAOYSA-N CC(C)(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 NZLZPEXQNSVHJE-UHFFFAOYSA-N 0.000 description 1
- HHNDFWVUGYHISZ-UHFFFAOYSA-N CC(C)(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 HHNDFWVUGYHISZ-UHFFFAOYSA-N 0.000 description 1
- SDZSSGGMKDCXRP-UHFFFAOYSA-N CC(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CC(C)C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 SDZSSGGMKDCXRP-UHFFFAOYSA-N 0.000 description 1
- MOPPEKSIVUKRQS-UHFFFAOYSA-N CCC(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 Chemical compound CCC(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)nc1 MOPPEKSIVUKRQS-UHFFFAOYSA-N 0.000 description 1
- HEGMTAXNPHIWBZ-UHFFFAOYSA-N CCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c3nnc(NC(Cc(cc4)ccc4OC)=O)[s]3)=O)cc2)nc1 Chemical compound CCC(CC1)CCC1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c3nnc(NC(Cc(cc4)ccc4OC)=O)[s]3)=O)cc2)nc1 HEGMTAXNPHIWBZ-UHFFFAOYSA-N 0.000 description 1
- FPMIAQREJSIFNC-YOVUVYLBSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(N)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(N)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 FPMIAQREJSIFNC-YOVUVYLBSA-N 0.000 description 1
- CQLYURUKAKQHMU-MXHUKOMYSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(NS(C)(=O)=O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(NS(C)(=O)=O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 CQLYURUKAKQHMU-MXHUKOMYSA-N 0.000 description 1
- ULEFYDDQESKYDR-UZNLYWMJSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(c(OC)cc(OC)c3)c3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(c(OC)cc(OC)c3)c3OC)=O)=O)cc2)nc1 ULEFYDDQESKYDR-UZNLYWMJSA-N 0.000 description 1
- PRCIDDKVESOQCM-MXHUKOMYSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)nc1 PRCIDDKVESOQCM-MXHUKOMYSA-N 0.000 description 1
- WDALJAQUDWTWMQ-QCCMBLGWSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3Cl)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3Cl)ccc3OC)=O)=O)cc2)nc1 WDALJAQUDWTWMQ-QCCMBLGWSA-N 0.000 description 1
- SYQBCIVOYOLCIM-OKBFXJRSSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)nnc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(cc3)nnc3NC(Cc(cc3)ccc3OC)=O)=O)cc2)nc1 SYQBCIVOYOLCIM-OKBFXJRSSA-N 0.000 description 1
- ASURZAULCFYJJD-JFGCXZKZSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(c(C(F)(F)F)c3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(c(C(F)(F)F)c3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 ASURZAULCFYJJD-JFGCXZKZSA-N 0.000 description 1
- VNEFUMRZFAEGDM-OKBFXJRSSA-N CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(cc3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 Chemical compound CC[C@H](CC1)CC[C@@H]1C(CC1)CC=C1c1cnc(-c2ccc(CN(CC(O)=O)C(c(ccc(NC(Cc(cc3)ccc3OC)=O)c3Cl)c3Cl)=O)cc2)nc1 VNEFUMRZFAEGDM-OKBFXJRSSA-N 0.000 description 1
- MMWPDCXNGLPVBH-UHFFFAOYSA-N COc1cc(C(F)(F)F)c(CC(Nc(cc2)ccc2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C(F)(F)F)=O)=O)cc1 Chemical compound COc1cc(C(F)(F)F)c(CC(Nc(cc2)ccc2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C(F)(F)F)=O)=O)cc1 MMWPDCXNGLPVBH-UHFFFAOYSA-N 0.000 description 1
- QHDCUGAXLGKZJU-YBQHVXFOSA-N COc1ccc(CC(N(CCC2)[C@@H]2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(N(CCC2)[C@@H]2C(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 QHDCUGAXLGKZJU-YBQHVXFOSA-N 0.000 description 1
- NLPALMYMHJALJL-UHFFFAOYSA-N COc1ccc(CC(NCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(NCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 NLPALMYMHJALJL-UHFFFAOYSA-N 0.000 description 1
- GGOYJBFLGLWJFP-UHFFFAOYSA-N COc1ccc(CC(NCCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 Chemical compound COc1ccc(CC(NCCC(N(CC(O)=O)Cc(cc2)ccc2-c(nc2)ncc2C(CC2)=CCC2C2CCCCC2)=O)=O)cc1 GGOYJBFLGLWJFP-UHFFFAOYSA-N 0.000 description 1
- QTZORYHBAZQHRB-UHFFFAOYSA-N COc1ccc(CC(Nc2nnc(C(N(CC(O)=O)Cc(cc3)ccc3-c(nc3)ncc3C(CC3)=CCC3C3CCCCC3)=O)[s]2)=O)cc1 Chemical compound COc1ccc(CC(Nc2nnc(C(N(CC(O)=O)Cc(cc3)ccc3-c(nc3)ncc3C(CC3)=CCC3C3CCCCC3)=O)[s]2)=O)cc1 QTZORYHBAZQHRB-UHFFFAOYSA-N 0.000 description 1
- IOEAJXFOQFKBSL-UHFFFAOYSA-N Cc1cc(OC)ccc1CC(Nc(cc1)ccc1C(N(CC(O)=O)Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C1CCCCC1)=O)=O Chemical compound Cc1cc(OC)ccc1CC(Nc(cc1)ccc1C(N(CC(O)=O)Cc(cc1)ccc1-c(nc1)ncc1C(CC1)=CCC1C1CCCCC1)=O)=O IOEAJXFOQFKBSL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491892P | 2017-04-28 | 2017-04-28 | |
| US62/491,892 | 2017-04-28 | ||
| PCT/US2018/029597 WO2018200833A1 (en) | 2017-04-28 | 2018-04-26 | Novel glp-1 receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518571A JP2020518571A (ja) | 2020-06-25 |
| JP2020518571A5 true JP2020518571A5 (enExample) | 2021-06-10 |
| JP7116745B2 JP7116745B2 (ja) | 2022-08-10 |
Family
ID=62117189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558778A Active JP7116745B2 (ja) | 2017-04-28 | 2018-04-26 | 新規なｇｌｐ－１受容体モジュレーター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11530205B2 (enExample) |
| EP (1) | EP3615524B1 (enExample) |
| JP (1) | JP7116745B2 (enExample) |
| AU (1) | AU2018260686B2 (enExample) |
| CA (1) | CA3060424A1 (enExample) |
| ES (1) | ES2937835T3 (enExample) |
| WO (1) | WO2018200833A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109503510B (zh) * | 2019-01-03 | 2020-07-03 | 山东大学 | 一种防龋抗菌的噻唑类化合物及其制备方法 |
| GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| CN114181187A (zh) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | 一种4-甲磺酰胺基丁酰胺化合物的制备方法 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2713722T3 (en) * | 2011-05-31 | 2017-07-03 | Celgene Int Ii Sarl | Newly known GLP-1 receptor stabilizers and modulators |
| RU2634896C2 (ru) | 2011-12-12 | 2017-11-08 | Селджин Интернэшнл Ii Сарл | Новые модуляторы рецептора glp-1 |
| CA2913791A1 (en) * | 2013-06-11 | 2014-12-18 | Receptos, Inc. | Novel glp-1 receptor modulators |
| KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| AU2015292356B2 (en) * | 2014-07-25 | 2020-02-06 | Receptos Llc | Novel GLP-1 receptor modulators |
| ES2844573T3 (es) * | 2014-12-10 | 2021-07-22 | Receptos Llc | Moduladores del receptor de GLP-1 |
-
2018
- 2018-04-26 WO PCT/US2018/029597 patent/WO2018200833A1/en not_active Ceased
- 2018-04-26 CA CA3060424A patent/CA3060424A1/en active Pending
- 2018-04-26 ES ES18723347T patent/ES2937835T3/es active Active
- 2018-04-26 AU AU2018260686A patent/AU2018260686B2/en not_active Ceased
- 2018-04-26 JP JP2019558778A patent/JP7116745B2/ja active Active
- 2018-04-26 US US16/608,134 patent/US11530205B2/en active Active
- 2018-04-26 EP EP18723347.3A patent/EP3615524B1/en active Active